Pledge Biosciences
Pledge Therapeutics is a pioneering drug discovery company focused on developing innovative therapeutics for challenging disease targets. They merge cell and structure-based data with information-driven strategies to build a cutting-edge drug discovery engine, harnessing advanced biostructural, biochemical, and biophysical technologies to design first-in-class therapeutics. Their mission is to revolutionize the standard of care by targeting some of the most exciting yet out-of-reach disease targets, including in immuno-oncology and antiviral research.
Industries
Nr. of Employees
small (1-50)
Pledge Biosciences
Canton, Massachusetts, United States, North America
Products
Orally available anti-Polyomavirus preclinical candidate
A first-in-class small-molecule antiviral developed to suppress BK virus reactivation and replication with low-nanomolar potency and an oral dosing profile; reported to be progressing toward IND-enabling studies for prophylactic and therapeutic use in transplant-related polyomavirus disease.
Broad-spectrum coronavirus treatment (preclinical)
Discovery program focused on developing a novel, broad-spectrum therapeutic approach to prevent and treat variants of SARS-CoV-2 and future coronaviruses.
First-in-class gram-negative antibacterial program (preclinical)
Preclinical discovery program for a novel gram-negative antibacterial agent; target details not disclosed on source material.
Orally available anti-Polyomavirus preclinical candidate
A first-in-class small-molecule antiviral developed to suppress BK virus reactivation and replication with low-nanomolar potency and an oral dosing profile; reported to be progressing toward IND-enabling studies for prophylactic and therapeutic use in transplant-related polyomavirus disease.
Broad-spectrum coronavirus treatment (preclinical)
Discovery program focused on developing a novel, broad-spectrum therapeutic approach to prevent and treat variants of SARS-CoV-2 and future coronaviruses.
First-in-class gram-negative antibacterial program (preclinical)
Preclinical discovery program for a novel gram-negative antibacterial agent; target details not disclosed on source material.
Services
Structure-based small-molecule and biologics discovery platform
Integrated discovery platform that combines structural biology, biophysics, medicinal chemistry and computational modelling to generate and optimize preclinical drug candidates.
Preclinical discovery services in antiviral and immuno-oncology programs
End-to-end preclinical discovery activities including hit generation, assay development, mechanism-of-action studies, PK profiling and candidate advancement for antiviral and immune-oncology targets.
Structure-based small-molecule and biologics discovery platform
Integrated discovery platform that combines structural biology, biophysics, medicinal chemistry and computational modelling to generate and optimize preclinical drug candidates.
Preclinical discovery services in antiviral and immuno-oncology programs
End-to-end preclinical discovery activities including hit generation, assay development, mechanism-of-action studies, PK profiling and candidate advancement for antiviral and immune-oncology targets.
Expertise Areas
- Structure-based drug design
- Immuno-oncology drug discovery
- Antiviral and anti-infective drug development
- Medicinal chemistry and lead optimization
Key Technologies
- X-ray crystallography
- Structure-guided small-molecule design
- Molecular dynamics simulation
- Cheminformatics